Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians

References

• Averill, J. B. (2002). Matrix analysis as a complementary analytic strategy in qualitative inquiry. Qualitative Health Research, 12(6), 855–866.
   PubMed Web of Science ®Google Scholar
• Biglan, K. M., Ross, C. A., Langbehn, D. R., Aylward, E. H., Stout, J. C., Queller, S., … Paulsen, J. S. (2009). Motor abnormalities in premanifest persons with Huntington's disease: The predict-hd study. Movement Disorders, 24(12), 1763–1772.
   PubMed Web of Science ®Google Scholar
• Bonelli, R. M., & Hofmann, P. (2007). A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opinion on Pharmacotherapy, 8(2), 141–153.
   PubMed Web of Science ®Google Scholar
• Busse, M., Quinn, L., Dawes, H., Jones, C., Kelson, M., Poile, V., … Hood, K. (2014). Supporting physical activity engagement in people with Huntington's disease (engage-hd): Study protocol for a randomized controlled feasibility trial. Trials, 15, 487.
   PubMed Web of Science ®Google Scholar
• Busse, M., Quinn, L., Debono, K., Jones, K., Collett, J., Playle, R., … Rosser, A. (2013). A randomized feasibility study of a 12-week community-based exercise program for people with Huntington's disease. Journal of Neurologic Physical Therapy: JNPT, 37(4), 149–158.
   PubMed Web of Science ®Google Scholar
• Busse, M. E., Wiles, C. M., & Rosser, A. E. (2009). Mobility and falls in people with Huntington's disease. Journal of Neurology Neurosurgery & Psychiatry, 80(1), 88–90.
   PubMed Web of Science ®Google Scholar
• Carlozzi, N. E., Downing, N. R., McCormack, M. K., Schilling, S. G., Perlmutter, J. S., Hahn, E. A., … Nance, M. A. (2016). New measures to capture end of life concerns in Huntington disease: Meaning and purpose and concern with death and dying from hdqlife (a patient-reported outcomes measurement system). Quality of Life Research, 25(10), 2403–2415.
   PubMed Web of Science ®Google Scholar
• Carlozzi, N. E., Downing, N. R., Schilling, S. G., Lai, J.-S., Goodnight, S. M., Miner, J. A., & A. Frank, S. (2016). The development of a new computer adaptive test to evaluate chorea in Huntington disease: Hdqlife chorea. Quality of Life Research, 25(10), 2429–2439.
   PubMed Web of Science ®Google Scholar
• Carlozzi, N. E., Hahn, E. A., Frank, S. A., Perlmutter, J. S., Downing, N. D., McCormack, M. K., … Schilling, S. G. (2018). A new measure for end of life planning, preparation, and preferences in Huntington disease: Hdqlife end of life planning. Journal of Neurology, 265(1), 98–107.
   PubMed Web of Science ®Google Scholar
• Carlozzi, N. E., Hahn, E. A., Goodnight, S. M., Kratz, A. L., Paulsen, J. S., Stout, J. C., … Ready, R. E. (2018). Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (neuro-qol) social functioning measures. Psychological Assessment, 30(4), 450–458.
   PubMed Web of Science ®Google Scholar
• Carlozzi, N. E., Miciura, A., Migliore, N., & Dayalu, P. (2014). Understanding the outcomes measures used in Huntington disease pharmacological trials: A systematic review. Journal of Huntington's Disease, 3(3), 233–252.
   PubMedGoogle Scholar
• Carlozzi, N. E., Ready, R. E., Frank, S., Cella, D., Hahn, E. A., Goodnight, S. M., … Dayalu, P. (2017). Patient-reported outcomes in Huntington's disease: Quality of life in neurological disorders (neuro-qol) and Huntington's disease health-related quality of life (hdqlife) physical function measures. Movement Disorders, 32(7), 1096–1102.
   PubMed Web of Science ®Google Scholar
• Carlozzi, N. E., Schilling, S. G., Lai, J. S., Paulsen, J. S., Hahn, E. A., Perlmutter, J. S., … Cella, D. (2016). Hdqlife: Development and assessment of health-related quality of life in Huntington disease (hd). Quality of Life Research, 25(10), 2441–2455.
   PubMed Web of Science ®Google Scholar
• Carlozzi, N. E., Schilling, S. G., Lai, J. S., Perlmutter, J. S., Nance, M. A., Waljee, J. F., … Dayalu, P. (2016). Hdqlife: The development of two new computer adaptive tests for use in Huntington disease, speech difficulties, and swallowing difficulties. Quality of Life Research, 25(10), 2417–2427.
   PubMed Web of Science ®Google Scholar
• Carlozzi, N. E., & Tulsky, D. S. (2013). Identification of health-related quality of life (hrqol) issues relevant to individuals with Huntington disease. Journal of Health Psychology, 18(2), 212–225.
   PubMed Web of Science ®Google Scholar
• Carlozzi, N. E., Tulsky, D. S., & Kisala, P. A. (2011). Traumatic brain injury patient-reported outcome measure: Identification of health-related quality-of-life issues relevant to individuals with traumatic brain injury. Archives of Physical Medicine and Rehabilitation, 92(10 Suppl), S52–S60.
   PubMed Web of Science ®Google Scholar
• Cella, D. F. (1995). Measuring quality of life in palliative care. Seminars in Oncology, 22(2 Suppl 3), 73–81.
   PubMed Web of Science ®Google Scholar
• Chen, J. J., Ondo, W. G., Dashtipour, K., & Swope, D. M. (2012). Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clinical Therapeutics, 34(7), 1487–1504.
   PubMed Web of Science ®Google Scholar
• Dawes, H., Collett, J., Debono, K., Quinn, L., Jones, K., Kelson, M. J., … Busse, M. (2015). Exercise testing and training in people with Huntington's disease. Clinical Rehabilitation, 29(2), 196–206.
   PubMed Web of Science ®Google Scholar
• Dorey, J., Clay, E., Khemiri, A., Belhadj, A., Cubillo, P. T., & Toumi, M. (2016). The quality of life of Spanish patients with Huntington's disease measured with h-qol-i and eq-5d. J Mark Access Health Policy, 4, 1–8.
   Google Scholar
• Dorsey, R., Biglan, K., Eberly, S., Auinger, P., Brocht, A., Umeh, C. C., … Frank, S. (2011). Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: Results from the tetra-hd study. PLoS Currents, 3, RRN1283.
   PubMedGoogle Scholar
• Erwin, C., Williams, J. K., Juhl, A. R., Mengeling, M., Mills, J. A., & Bombard, Y., … , I-RESPOND-HD Investigators of the Huntington Study Group (2010). Perception, experience, and response to genetic discrimination in Huntington disease: The international respond-hd study. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 153B(5), 1081–1093.
   PubMed Web of Science ®Google Scholar
• Frank, S. (2009). Tetrabenazine as anti-chorea therapy in Huntington disease: An open-label continuation study. Huntington study group/tetra-hd investigators. BMC Neurology, 9, 62.
   PubMed Web of Science ®Google Scholar
• Frank, S. (2010). Tetrabenazine: The first approved drug for the treatment of chorea in us patients with Huntington disease. Neuropsychiatric Disease and Treatment, 6, 657–665.
   PubMed Web of Science ®Google Scholar
• Frank, S., & Jankovic, J. (2010). Advances in the pharmacological management of Huntington's disease. Drugs, 70(5), 561–571.
   PubMed Web of Science ®Google Scholar
• Frank, S., Ondo, W., Fahn, S., Hunter, C., Oakes, D., Plumb, S., … Jankovic, J. (2008). A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clinical Neuropharmacology, 31(3), 127–133.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group, Frank, S., Testa, C. M., Stamler, D., Kayson, E., Davis, C., … Christopher, E. (2016). Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial. JAMA, 316(1), 40–50.
   PubMed Web of Science ®Google Scholar
• Fritz, N. E., Boileau, N. R., Stout, J. C., Ready, R., Perlmutter, J. S., Paulsen, J. S., … Carlozzi, N. E. (2018). Relationships among apathy, health-related quality of life, and function in Huntington's disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 30, 194–201.
   PubMed Web of Science ®Google Scholar
• Geschwind, M. D., & Paras, N. (2016). Deutetrabenazine for treatment of chorea in Huntington disease. JAMA, 316(1), 33–35.
   PubMed Web of Science ®Google Scholar
• Grimbergen, Y. A., Knol, M. J., Bloem, B. R., Kremer, B. P., Roos, R. A., & Munneke, M. (2008). Falls and gait disturbances in Huntington's disease. Movement Disorders, 23(7), 970–976.
   PubMed Web of Science ®Google Scholar
• Guo, Z., Rudow, G., Pletnikova, O., Codispoti, K.-E., Orr, B. A., Crain, B. J., … Troncoso, J. C. (2012). Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Movement Disorders, 27(11), 1379–1386.
   PubMed Web of Science ®Google Scholar
• Hartelius, L., Jonsson, M., Rickeberg, A., & Laakso, K. (2010). Communication and Huntington's disease: Qualitative interviews and focus groups with persons with Huntington's disease, family members, and carers. International Journal of Language & Communication Disorders, 45(3), 381–393.
   PubMed Web of Science ®Google Scholar
• Helder, D. I., Kaptein, A. A., van Kempen, G. M., van Houwelingen, J. C., & Roos, R. A. (2001). Impact of Huntington's disease on quality of life. Movement Disorders, 16(2), 325–330.
   PubMed Web of Science ®Google Scholar
• Helkala, E. L., Koivisto, K., Hanninen, T., Vanhanen, M., Kervinen, K., Kuusisto, J., … Riekkinen, P. (1995). The association of apolipoprotein e polymorphism with memory: A population based study. Neuroscience Letters, 191(3), 141–144.
   PubMed Web of Science ®Google Scholar
• Ho, A. K., Gilbert, A. S., Mason, S. L., Goodman, A. O., & Barker, R. A. (2009). Health-related quality of life in Huntington's disease: Which factors matter most? Movement Disorders, 24(4), 574–578.
   PubMed Web of Science ®Google Scholar
• Ho, A. K., & Hocaoglu, M. B. (2011). Impact of Huntington's across the entire disease spectrum: The phases and stages of disease from the patient perspective. Clinical Genetics, 80(3), 235–239.
   PubMed Web of Science ®Google Scholar
• Ho, A. K., Robbins, A. O., Walters, S. J., Kaptoge, S., Sahakian, B. J., & Barker, R. A. (2004). Health-related quality of life in Huntington's disease: A comparison of two generic instruments, sf-36 and sip. Movement Disorders, 19(11), 1341–1348.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group. (2006). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology, 66(3), 366–372.
   PubMed Web of Science ®Google Scholar
• Jacobs, M., Hart, E. P., van Zwet, E. W., Bentivoglio, A. R., Burgunder, J. M., Craufurd, D., … Roos, R. A. C. (2016). Progression of motor subtypes in Huntington's disease: A 6-year follow-up study. Journal of Neurology, 263(10), 2080–2085.
   PubMed Web of Science ®Google Scholar
• Jankovic, J., & Roos, R. A. (2014). Chorea associated with Huntington's disease: To treat or not to treat? Movement Disorders, 29(11), 1414–1418.
   PubMed Web of Science ®Google Scholar
• Jarrett, R. L. (1993). Focus group interviewing with low-income minority populations: A research experience. In D. L. Morgan (Ed.), Successful focus groups: Advancing the state of the Art (pp. 184–201). Newbury Park, CA: Sage.
   Google Scholar
• Jarrett, R. L. (1994). Living poor-family-life among single-parent, African-American women. Social Problems, 41(1), 30–49.
   Web of Science ®Google Scholar
• Kaptein, A. A., Scharloo, M., Helder, D. I., Snoei, L., van Kempen, G. M. J., Weinman, J., … Roos, R. A. C. (2007). Quality of life in couples living with Huntington's disease: The role of patients’ and partners’ illness perceptions. Quality of Life Research, 16(5), 793–801.
   PubMed Web of Science ®Google Scholar
• Khalil, H., Quinn, L., van Deursen, R., Dawes, H., Playle, R., Rosser, A., & Busse, M. (2013). What effect does a structured home-based exercise programme have on people with Huntington's disease? A randomized, controlled pilot study. Clinical Rehabilitation, 27(7), 646–658.
   PubMed Web of Science ®Google Scholar
• Kisala, P., & Tulsky, D. (2010). Opportunities for cat applications in medical rehabilitation: Development of targeted item banks. journal of Applied Measurement, 11(3), 315–330.
   PubMedGoogle Scholar
• Kisala, P. A., Victorson, D., Pace, N., Heinemann, A. W., Choi, S. W., & Tulsky, D. S. (2015). Measuring psychological trauma after spinal cord injury: Development and psychometric characteristics of the sci-qol psychological trauma item bank and short form. The Journal of Spinal Cord Medicine, 38(3), 326–334.
   PubMed Web of Science ®Google Scholar
• Kloos, A. D., Kegelmeyer, D. A., Young, G. S., & Kostyk, S. K. (2010). Fall risk assessment using the tinetti mobility test in individuals with Huntington's disease. Movement Disorders, 25(16), 2838–2844.
   PubMed Web of Science ®Google Scholar
• Lai, J. S., Goodnight, S., Downing, N. R., Ready, R. E., Paulsen, J. S., Kratz, A. L., … Carlozzi, N. E. (2018). Evaluating cognition in individuals with Huntington disease: Neuro-qol cognitive functioning measures. Quality of Life Research, 27(3), 811–822.
   PubMed Web of Science ®Google Scholar
• Lincoln, Y. S., & Guba, E. G. (1985). Naturalistic inquiry. Beverly Hills, CA: Sage.
   Google Scholar
• Lowit, A., & van Teijlingen, E. R. (2005). Avoidance as a strategy of (not) coping: Qualitative interviews with carers of Huntington's disease patients. BMC Family Practice, 6, 38.
   PubMedGoogle Scholar
• Mahant, N., McCusker, E. A., Byth, K., & Graham, S. (2003). Huntington's disease: Clinical correlates of disability and progression. Neurology, 61(8), 1085–1092.
   PubMed Web of Science ®Google Scholar
• Mann, R. K., Edwards, R., Zhou, J., Fenney, A., Jog, M., & Duval, C. (2012). Comparing movement patterns associated with Huntington's chorea and Parkinson's dyskinesia. Experimental Brain Research Experimentelle Hirnforschung Experimentation Cerebrale, 218(4), 639–654.
   PubMed Web of Science ®Google Scholar
• Marshall, F. J. (2006). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology, 66(3), 366–372.
   PubMed Web of Science ®Google Scholar
• Marshall, F. J., Walker, F., Frank, S., Oakes, D., Plumb, S., Factor, S. A., … Young, A. B. (2006). Tetrabenazine as antichorea therapy in Huntington disease – a randomized controlled trial. Neurology, 66(3), 366–372.
   PubMed Web of Science ®Google Scholar
• The Medical Letter, Inc. (2009). Tetrabenazine (xenazine) for Huntington's chorea. Medical Letter on Drugs & Therapeutics, 51(1304), 7–8.
   PubMed Web of Science ®Google Scholar
• Miles, M. B., Huberman, A. M., & Saldana, J. (2014). Qualitative data analysis: A methods sourcebook (3rd ed.). Thousand Oaks, CA: Sage.
   Google Scholar
• Nvivo qualitative data analysis software [computer program]. (n.d.). Version Version 102012.
   Google Scholar
• Ondo, W. G., Tintner, R., Thomas, M., & Jankovic, J. (2002). Tetrabenazine treatment for Huntington's disease-associated chorea. Clinical Neuropharmacology, 25(6), 300–302.
   PubMed Web of Science ®Google Scholar
• Paulsen, J. S., Nance, M., Kim, J. I., Carlozzi, N. E., Panegyres, P. K., Erwin, C., … Williams, J. K. (2013). A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Progress in Neurobiology, 110, 2–28.
   PubMed Web of Science ®Google Scholar
• Pidgeon, C., & Rickards, H. (2013). The pathophysiology and pharmacological treatment of Huntington disease. Behavioural Neurology, 26(4), 245–253.
   PubMed Web of Science ®Google Scholar
• Poon, L. H., Kang, G. A., & Lee, A. J. (2010). Role of tetrabenazine for Huntington's disease-associated chorea. Annals of Pharmacotherapy, 44(6), 1080–1089.
   PubMed Web of Science ®Google Scholar
• Quinn, L., Busse, M., Khalil, H., Richardson, S., Rosser, A., & Morris, H. (2010). Client and therapist views on exercise programmes for early-mid stage Parkinson's disease and Huntington's disease. Disability and Rehabilitation, 32(11), 917–928.
   PubMed Web of Science ®Google Scholar
• Quinn, L., Hamana, K., Kelson, M., Dawes, H., Collett, J., Townson, J., … Busse, M. (2016). A randomized, controlled trial of a multi-modal exercise intervention in Huntington's disease. Parkinsonism & Related Disorders, 31, 46–52.
   PubMed Web of Science ®Google Scholar
• Read, J., Jones, R., Owen, G., Leavitt, B. R., Coleman, A., Roos, R. A., … TRACK-HD investigators (2013). Quality of life in Huntington's disease: A comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners. Journal of Huntington's Disease, 2(2), 159–175.
   PubMedGoogle Scholar
• Ready, R. E., Mathews, M., Leserman, A., & Paulsen, J. S. (2008). Patient and caregiver quality of life in Huntington's disease. Movement Disorders, 23(5), 721–726.
   PubMed Web of Science ®Google Scholar
• Reilmann, R. (2016). Deutetrabenazine-not a revolution but welcome evolution for treating chorea in Huntington disease. Jama Neurology, 73, 1404–1406.
   PubMed Web of Science ®Google Scholar
• Rothing, M., Malterud, K., & Frich, J. C. (2015). Balancing needs as a family caregiver in Huntington's disease: A qualitative interview study. Health Soc Care Comm, 23(5), 569–576.
   PubMed Web of Science ®Google Scholar
• Savani, A. A., Login, I. S., Marshall, F. J., Fahn, S., & Clarence-Smith, K. (2007). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology, 68(10), 797–797.
   PubMed Web of Science ®Google Scholar
• Scott, L. J. (2011). Tetrabenazine: For chorea associated with Huntington's disease. CNS Drugs, 25(12), 1073–1085.
   PubMed Web of Science ®Google Scholar
• Setter, S. M., Neumiller, J. J., Dobbins, E. K., Wood, L., Clark, J., DuVall, C. A. K., & Santiago, A. (2009). Treatment of chorea associated with Huntington's disease: Focus on tetrabenazine. The Consultant Pharmacist: The Journal of the American Society of Consultant Pharmacists, 24(7), 524–537.
   PubMedGoogle Scholar
• Stewart, D. W., & Shamdasani, P. N. (1990). Focus groups: Theory and practice. London: Sage.
   Google Scholar
• Strauss, A. L., & Corbin, J. M. (1998). Basics of qualitative research: Techniques and procedures for developing grounded theory (2nd ed.). Thousand Oaks, CA: Sage.
   Google Scholar
• Taylor, S. D. (2004). Predictive genetic test decisions for Huntington's disease: Context, appraisal and new moral imperatives. Social Science & Medicine, 58(1), 137–149.
   PubMed Web of Science ®Google Scholar
• Taylor, S. D. (2005). Predictive genetic test decisions for Huntington's disease: Elucidating the test/no-test dichotomy. Journal of Health Psychology, 10(4), 597–612.
   PubMed Web of Science ®Google Scholar
• Thorley, E. M., Iyer, R. G., Wicks, P., Curran, C., Gandhi, S. K., Abler, V., … Carlozzi, N. E. (2018). Understanding how chorea affects health-related quality of life in Huntington disease: An online survey of patients and caregivers in the United States. The Patient, 11, 547–559.
   PubMedGoogle Scholar
• Tian, J., Herdman, S. J., Zee, D. S., & Folstein, S. E. (1992). Postural stability in patients with Huntington's disease. Neurology, 42(6), 1232–1232.
   PubMed Web of Science ®Google Scholar
• Tulsky, D. S., Kisala, P. A., Kalpakjian, C. Z., Bombardier, C. H., Pohlig, R. T., Heinemann, A. W., … Choi, S. W. (2015). Measuring depression after spinal cord injury: Development and psychometric characteristics of the sci-qol depression item bank and linkage with phq-9. The Journal of Spinal Cord Medicine, 38(3), 335–346.
   PubMed Web of Science ®Google Scholar
• van Vugt, J. P., Piet, K. K., Vink, L. J., Siesling, S., Zwinderman, A. H., Middelkoop, H. A. M., & Roos, R. A. C. (2004). Objective assessment of motor slowness in Huntington's disease: Clinical correlates and 2-year follow-up. Movement Disorders, 19(3), 285–297.
   PubMed Web of Science ®Google Scholar
• van Vugt, J. P., Siesling, S., Piet, K. K., Zwinderman, A. H., Middelkoop, H. A. M., van Hilten, J. J., & Roos, R. A. C. (2001). Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington's disease. Movement Disorders, 16(3), 481–488.
   PubMed Web of Science ®Google Scholar
• van Walsem, M. R., Howe, E. I., Ruud, G. A., Frich, J. C., & Andelic, N. (2017). Health-related quality of life and unmet healthcare needs in Huntington's disease. Health and Quality of Life Outcomes, 15(1), 6.
   PubMedGoogle Scholar
• Venuto, C. S., McGarry, A., Ma, Q., & Kieburtz, K. (2012). Pharmacologic approaches to the treatment of Huntington's disease. Movement Disorders, 27(1), 31–41.
   PubMed Web of Science ®Google Scholar
• Victorson, D., Carlozzi, N. E., Frank, S., Beaumont, J. L., Cheng, W., Gorin, B., … Sung, V. (2014). Identifying motor, emotional-behavioral, and cognitive deficits that comprise the triad of hd symptoms from patient, caregiver, and provider perspectives. Tremor Other Hyperkinet Mov (N Y), 4, 224.
   PubMedGoogle Scholar
• Walker, J. S., & Koroloff, N. (2007). Grounded theory and backward mapping: Exploring the implementation context for wraparound. The Journal of Behavioral Health Services & Research, 34(4), 443–458.
   PubMed Web of Science ®Google Scholar
• Walker, D., & Myrick, F. (2006). Grounded theory: An exploration of process and procedure. Qualitative Health Research, 16(4), 547–559.
   PubMed Web of Science ®Google Scholar
• Wexler, A. (2010). Stigma, history, and Huntington's disease. The Lancet, 376(9734), 18–19.
   PubMed Web of Science ®Google Scholar
• Williams, J. K., Erwin, C., Juhl, A. R., Mengeling, M., Bombard, Y., & Hayden, M. R., … the I-RESPOND-HD Investigators of the Huntington Study Group (2010). In their own words: Reports of stigma and genetic discrimination by people at risk for Huntington disease in the international respond-hd study. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 153B(6), 1150–1159.
   PubMed Web of Science ®Google Scholar
• Yero, T., & Rey, J. A. (2008). Tetrabenazine (xenazine), an fda-approved treatment option for Huntington's disease-related chorea. P and T, 33(12), 690–694.
   PubMedGoogle Scholar
• Zielonka, D., Ren, M., De Michele, G., Roos, R. A. C., Squitieri, F., Bentivoglio, A. R., … Landwehrmeyer, G. B. (2018). The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease. Parkinsonism & Related Disorders, 49, 42–47.
   PubMed Web of Science ®Google Scholar